Sam Fazeli

Oh, no, sorry, sorry, sorry, sorry, sorry, sorry to stop you.

I meant antibody, i.e.

a PD-L1 antibody versus a PD-1 antibody.

Well, so we're going to be all sitting there comparing PCR rates between EVs.

Was it three or four?

Keynote 905 and Volga then.

We look forward to the data.

Sorry, when are we expecting that?

Okay, cool.

And then, of course, we've got the...

We had the rivulogostomic plus dato in tropion pantumar 03, which includes, we've got that coming, both first and second line.

And what's the plan on that now?

I mean, you know, first line to challenge EV Pembro, is that the idea or...?

So, Susan, we've...

eaten one hour of your time, which is much more valuable than mine, that's for sure.

And we didn't talk about non-small cell, we didn't talk about gastric, hepatocellular, I had all these things here, colorectal, ovarian, et cetera, of course.

But that's the problem with AstraZeneca.

You've got things in, fingers in all kinds of pies.

I just wanted to highlight, you did have some Artemido 1 data,

which I got excited by.